111-POS

Abstract

Methods A total of 24 preeclampsia was enrolled. All pregnant were Caucasian, non-smoker, BMI 30 Kg/m2. At the time of clinic attendance, venous blood samples were collected (EDTA), tubes centrifuged and plasma samples were stored at −70 °C. sFLT-1 plasma levels were measured by ELISA (DVR100B). MiRs were extracted from plasma using the miRNeasy Serum/Plasma Kit. Samples from three preeclampsia presenting the highest level of sFLT-1 and three presenting the lowest levels were choose to performed a screening using the Human Plasma miRNA PCR array (MIHS-106Z) following the manufacturer’s protocol. After screening individual miRNAs were quantified by miScript SYBR Green qRT-PCR assays using specifics primers. Results Among 84 miRNAs evaluated by PCR-array, 4 were differentially expressed between groups considering a fold-change ⩾3.0: miR-195-5p, miR-16-5p and miR-19b-3p were more expressed in high group and miR-375 in low group. The next step was performed real-time qRT-PCR in all samples (n = 24) and verify correlations with sFLT-1. We use two extremes of analysis: 50% and 25% of sFLT-1 levels in the 24 samples (n = 12 in low and n = 12 in high group considering 50% analysis; and n = 6 in low and n = 6 in high group considering 25% analysis). The result is demonstrated in Figure. Conclusions We concluded that miR195-5p is associated with higher levels of sFLT-1 in preeclampsia. Financial Support: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). Disclosures V. Sandrim: None. K. Fernandes: None. R. Cavalli: None.